-+ 0.00%
-+ 0.00%
-+ 0.00%
FDA approves Foundation Medicine test for Wilserdly combination therapy
Share
Listen to the news
FDA approves Foundation Medicine test for Wilserdly combination therapy
  • FDA approved Foundation Medicine's FoundationOne Liquid CDx as the first companion diagnostic for WILSERDLY (giredestrant) combined with everolimus.
  • The test identifies adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer who may qualify for the combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foundation Medicine Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending